EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period

Hiba Dagher, Anne-Marie Chaftari iD, Ishwaria M Subbiah, Alexandre E Malek, Ying Jiang, Peter Lamie, Bruno Granwehr, Teny John, Eduardo Yepez, Jovan Borjan, Cielito Reyes-Gibby iD, Mary Flores und 8 weitere

eLife · 2023

DOI: 10.7554/elife.81182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Hiba Dagher und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease in non-cancer patients. The long-term consequences of COVID-19 are not fully understood particularly in the cancer patient population. The purpose of this study is to assess post-acute sequelae of SARS-CoV-2 infection (PASC) in cancer patients following acute COVID-19 recovery.

Methods

We identified cancer patients at MD Anderson Cancer Center who were diagnosed with COVID-19 disease between March 1, 2020, and September 1, 2020, and followed them till May 2021. To assess PASC, we collected patients reported outcomes through questionnaires that were sent to patients daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then monthly thereafter. We also reviewed patients’ electronic medical records to capture the persistence or emergence of new COVID19-related symptoms reported during any clinic or hospital encounter beyond 30 days of the acute illness and up to 14 months.

Results

We included 312 cancer patients with a median age of 57 years (18–86). The majority of patients had solid tumors (75%). Of the 312 patients, 188 (60%) reported long COVID-19 symptoms with a median duration of 7 months and up to 14 months after COVID-19 diagnosis. The most common symptoms reported included fatigue (82%), sleep disturbances (78%), myalgias (67%), and gastrointestinal symptoms (61%), followed by headache, altered smell or taste, dyspnea (47%), and cough (46%). A higher number of females reported a persistence of symptoms compared to males (63% vs. 37%; p=0.036). Cancer type, neutropenia, lymphocytopenia, and hospital admission during acute COVID-19 disease were comparable in both groups. Among the 188 patients with PASC, only 16 (8.5%) were re-admitted for COVID-related reasons.

Conclusions

More than one out of two cancer patients, and more likely females, report PASC that may persist beyond 6 months and even 1 year. The most common symptoms are non-respiratory and consist of fatigue, sleep disturbance, myalgia, and gastrointestinal symptoms. Most of the cancer patients with PASC were managed on outpatient basis with only 8.5% requiring a COVID-19-related re-admission. Funding: This research is supported by the National Institutes of Health/National Cancer Institute under award number P30CA016672, which supports the MD Anderson Cancer Center Clinical Trials Office. The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsUnited StatesFemaleMaleHumansAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overPost-Acute COVID-19 SyndromeCOVID-19 TestingSARS-CoV-2Fatigue

Stichwörter der Autor:innen

COVID-19cancer biologycancer patientsimmunocompromisedlong COVIDmedicineviruses

Autor:innen und Institutionen

  • Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, United States.
  • Integrative Medicine Program, The University of Texas MD Anderson Cancer Center, Houston, United States.
  • Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States.
  • Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, United States.
  • Emergency Medicine-Research, The University of Texas MD Anderson Cancer Center, Houston, United States.
  • Gastroenterology Research, The University of Texas MD Anderson Cancer Center, Houston, United States.

ORCID-Profile: Anne-Marie Chaftari, Cielito Reyes-Gibby

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Dagher, H., Chaftari, A. M., Subbiah, I. M., Malek, A. E., Jiang, Y., Lamie, P., Granwehr, B., John, T., Yepez, E., Borjan, J., Reyes-Gibby, C., Flores, M., Khawaja, F., Pande, M., Ali, N., Rojo, R., Karp, D. D., Chaftari, P., Hachem, R., & Raad, I. I. (2023). Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period. eLife. https://doi.org/10.7554/elife.81182

Vancouver

Dagher H, Chaftari AM, Subbiah IM, Malek AE, Jiang Y, Lamie P, et al. Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period. eLife. 2023. doi:10.7554/elife.81182

BibTeX
@article{Dagher2023,
  author = {Dagher, Hiba and Chaftari, Anne-Marie and Subbiah, Ishwaria M and Malek, Alexandre E and Jiang, Ying and Lamie, Peter and Granwehr, Bruno and John, Teny and Yepez, Eduardo and Borjan, Jovan and Reyes-Gibby, Cielito and Flores, Mary and Khawaja, Fareed and Pande, Mala and Ali, Noman and Rojo, Raniv and Karp, Daniel D and Chaftari, Patrick and Hachem, Ray and Raad, Issam I},
  title = {Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period},
  journal = {eLife},
  year = {2023},
  doi = {10.7554/elife.81182}
}
Kostenlos starten →